Literature DB >> 26272044

The expanding spectrum of EBV+ lymphomas.

Jonathan Said1.   

Abstract

In this issue of Blood, Nicolae et al at the National Cancer Institute describe a series of Epstein-Barr virus–positive (EBV+) diffuse large B-cell lymphomas (DLBCLs) in young patients (median age 23 years) without known immunodeficiency.

Entities:  

Mesh：

Year:  2015        PMID： 26272044     DOI： 10.1182/blood-2015-06-648097

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Investig Drugs       Date:  2016-10-31       Impact factor: 6.206

2.  EBV, an inhibited receptor kinase, and lymphoma.

Authors:  Richard F Ambinder
Journal:  Blood       Date:  2016-09-22       Impact factor: 22.113

Review 3.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

Review 4.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 5.  EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.

Authors:  Keri Toner; Catherine M Bollard
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

6.  Pediatric Pulmonary Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Review of the Literature.

Authors:  Eric X Wei; Roberto F Silva; James D Cotelingam; Rodney E Shackelford
Journal:  Case Rep Pathol       Date:  2017-10-08

7.  Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases.

Authors:  Changfei Qin; Yuhua Huang; Yanfen Feng; Min Li; Na Guo; Huilan Rao
Journal:  Diagn Pathol       Date:  2018-02-27       Impact factor: 2.644
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.